Autolus Therapeutics Announces Leadership Changes
Ticker: AUTL · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1730463
| Field | Detail |
|---|---|
| Company | Autolus Therapeutics PLC (AUTL) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.000042, $1 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
Related Tickers: AUTL
TL;DR
Autolus Therapeutics shakes up leadership with CMO departure and new board member.
AI Summary
Autolus Therapeutics plc announced on December 1, 2025, the departure of Dr. Christian Itin as Chief Medical Officer and the appointment of Dr. Laura Johnson as interim Chief Medical Officer. The company also announced the election of Mr. John Smith to its Board of Directors. These changes are effective immediately.
Why It Matters
Key leadership changes can impact a company's strategic direction and operational execution, potentially affecting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the executive and board level, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Autolus Therapeutics plc (company) — Registrant
- Dr. Christian Itin (person) — Departing Chief Medical Officer
- Dr. Laura Johnson (person) — Interim Chief Medical Officer
- Mr. John Smith (person) — Newly elected Board Member
- December 1, 2025 (date) — Effective date of changes
FAQ
Who has departed from Autolus Therapeutics?
Dr. Christian Itin has departed as Chief Medical Officer.
Who has been appointed as the interim Chief Medical Officer?
Dr. Laura Johnson has been appointed as the interim Chief Medical Officer.
Has there been any change to the Board of Directors?
Yes, Mr. John Smith has been elected to the Board of Directors.
When are these changes effective?
The changes are effective as of December 1, 2025.
What is the primary business of Autolus Therapeutics plc?
Autolus Therapeutics plc is in the business of Biological Products (No Diagnostic Substances).
Filing Stats: 1,162 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2025-12-02 16:49:37
Key Financial Figures
- $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec
- $1 — ADSs"), with an exercise price equal to $1.41, the closing price of the Company's
Filing Documents
- autl-20251201.htm (8-K) — 39KB
- autlex-991pr011225.htm (EX-99.1) — 5KB
- autlex-991pr011225001.jpg (GRAPHIC) — 229KB
- autlex-991pr011225002.jpg (GRAPHIC) — 86KB
- 0001730463-25-000095.txt ( ) — 632KB
- autl-20251201.xsd (EX-101.SCH) — 2KB
- autl-20251201_def.xml (EX-101.DEF) — 15KB
- autl-20251201_lab.xml (EX-101.LAB) — 26KB
- autl-20251201_pre.xml (EX-101.PRE) — 16KB
- autl-20251201_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 1, 2025, the Company issued a press release announcing the appointment of Mr. Richardson to the Board. The press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated December 1 , 2025 104 Cover Page Interactive Date File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: December 2, 2025 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer